HIV/AIDSESATANCT05420246
Efficacy and Safety of Ainuovirine Treating With AIDS Patients
An observational study of HIV/AIDS, run by Guangzhou 8th People's Hospital at 1 site in China.
Trial summary
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- HIV/AIDS
- What is being tested?
- Ainuovirine
- Type of treatment
- Pill or oral medicine
- How many people
- 450 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2022to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Patients who are prescribed to take including Ainuovirine regimen,because they are unable to tolerate the side-effect of or are not fit for the firstline free regimen in China,according to clinical judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.
Who may be able to join
- Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent
Who cannot join
- Patients who are participating in other interventional clinical trials;
- Patients who previously participated in the ACC007 study.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Guangzhou 8th People's Hospital, Guangzhou Medical University.
Guangzhou, Guangdong, 510060
Ke Yingchun, Master, 020-83803656, keyich@163.com
Li Linghua, PhD, 020-883710825, llheliza@126.com
About this study
Official title: The Efficacy and Safety of Ainuovirine in the Treatment of HIV-infected/AIDS Patients in China
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.
Read the detailed description
This study is an open-label, multicentered, single-arm and phase IV clinical trial.
450 HIV-infected patients who received Ainuovirine regimen (150mg, oral, qd) were included. At day 1 (1st collection as day 1), 3rd, 6th, 9th, 12th month, the rate of viral suppression and CD4+T cell count were calculated against baseline. In addition, the safety and drug compliance were also monitored.
Other indicators:
Demographic data (including gender, ethnicity, age, height, education level, occupation, route of infection), past medical history, smoking history, drug abuse history, hepatitis B markers, hepatitis C antibody, B ultrasound, chest X-ray, electrocardiogram, pregnancy test (Females of childbearing age): Day 1 (1st collection as Day 1), 1 time in total.
Vital signs (heart rate, blood pressure), body weight: 5 times on day 1 (the 1st collection was taken as day 1), 3rd, 6th, 9th, and 12th months.
- Conditions
- HIV/AIDS
- Being tested
- Ainuovirine
- Keywords
- Ainuovirine Therapy;Real World Study;HIV-1-infected patients
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AinuovirineDrug
The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
| Study group | Role | What they receive |
|---|---|---|
| These cases were given the treatment regimen including Ainuovirine | These cases were given the regimen including Ainuovirine (150mg, oral,qd) Receives: Drug: Ainuovirine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Virus suppression rate
ratio of HIV1-RNA < 20 copies/mL at 48 weeks of treatment
Measured: 48 weeks
Adverse events
Any adverse events reported during the observational period
Measured: 48 weeks
Secondary outcomes (2)
Immune reconstitution indicators
CD4 cell count, CD4 +/ CD8 + ratio (baseline to 48 weeks)
Measured: 48 weeks
Drug compliance
To explicit the number of people who have completed the treatment
Measured: 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2022
- Study start1 May 2022
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV/AIDSStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guangzhou 8th People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Linghua LI, Guangzhou 8th People's Hospital
- Investigators
- Ruosu Ying, Doctor, Study director, Guangzhou Eighth People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05420246
- Sponsor's protocol ID
- X220314682
- Acronym
- ESATA
- Status last verified
- Jun 2022
- First submitted
- 13 Jun 2022
- Last updated
- 15 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Safety of Ainuovirine in the Treatment of HIV-infected/AIDS Patients in China
- ClinicalTrials.gov ID
- NCT05420246
- Acronym / sponsor ID
- ESATA / X220314682
- Conditions
- HIV/AIDS
- Keywords
- Ainuovirine Therapy;Real World Study;HIV-1-infected patients
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- Guangzhou 8th People's HospitalUniversity, hospital or other
- Study start
- 1 May 2022 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 15 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.
Detailed description
This study is an open-label, multicentered, single-arm and phase IV clinical trial.
450 HIV-infected patients who received Ainuovirine regimen (150mg, oral, qd) were included. At day 1 (1st collection as day 1), 3rd, 6th, 9th, 12th month, the rate of viral suppression and CD4+T cell count were calculated against baseline. In addition, the safety and drug compliance were also monitored.
Other indicators:
Demographic data (including gender, ethnicity, age, height, education level, occupation, route of infection), past medical history, smoking history, drug abuse history, hepatitis B markers, hepatitis C antibody, B ultrasound, chest X-ray, electrocardiogram, pregnancy test (Females of childbearing age): Day 1 (1st collection as Day 1), 1 time in total.
Vital signs (heart rate, blood pressure), body weight: 5 times on day 1 (the 1st collection was taken as day 1), 3rd, 6th, 9th, and 12th months.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| These cases were given the treatment regimen including Ainuovirine | – | Drug: AinuovirineThese cases were given the regimen including Ainuovirine (150mg, oral,qd) |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients who are prescribed to take including Ainuovirine regimen,because they are unable to tolerate the side-effect of or are not fit for the firstline free regimen in China,according to clinical judgment, no matter of the HIV-RNA viral loads and CD4 cell counts.
Key inclusion criteria (1 listed)
- Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent
Key exclusion criteria (2 listed)
- Patients who are participating in other interventional clinical trials;
- Patients who previously participated in the ACC007 study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AinuovirineThe regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients. | Drug | These cases were given the treatment regimen including Ainuovirine |
Primary outcome
Virus suppression rate
Time frame: 48 weeks
ratio of HIV1-RNA < 20 copies/mL at 48 weeks of treatment
Adverse events
Time frame: 48 weeks
Any adverse events reported during the observational period
2 secondary outcomes
Immune reconstitution indicators
Time frame: 48 weeks
Drug compliance
Time frame: 48 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2022.
- Individual participant dataSharing planned: No
Related trials for HIV/AIDS
Enrolling by invitation
ORCHID: An Online Intervention for Persons With HIV (Miami)
HIV/AIDS, HPV Infection
Recruiting
Enhancing the Organizational Social Context to Improve Viral Suppression and Retention in HIV Care
HIV/AIDS
RecruitingPhase 1/2
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
HIV Associated Neurocognitive Disorder, HIV Dementia
Recruiting
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Randomized Trial
HIV/AIDS, HIV/AIDS Prevention
Active, not recruitingPhase 2
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ruosu Ying, Doctor study director
Guangzhou Eighth People's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of HIV/AIDS, run by Guangzhou 8th People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Linghua Li, Doctor (13725297174, llheliza@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Virus suppression rate (time frame: 48 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2022; AzTrials last refreshed its copy on 8 Nov 2026.